Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 6,915 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stimulation Clear all

Conditions: Metastatic Non-small Cell Lung Cancer
Interventions: Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab-paclitaxel, Pembrolizumab, Filgrastim, Pegylated filgrastim; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Phoenix, Arizona • Clermont, Florida • Orange City, Florida + 6 more

Conditions: Athletic Injuries
Interventions: Acute Cognitive Training, Non-stimulating Rest; Device · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 25 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Major Depressive Disorder
Interventions: TMS; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Chronic Renal Failure, Chronic Kidney Disease
Interventions: Epoetin Hospira, Epogen Amgen; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 73
States / cities: Azusa, California • Bakersfield, California • Long Beach, California + 51 more

Conditions: Speech
Interventions: TMS, Speaking Tasks; Device · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Status Epilepticus, Refractory Status Epilepticus
Interventions: Transcranial Direct Current Stimulation; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Spinal Cord Injuries
Interventions: High-frequency repetitive transcranial magnetic stimulation; Device
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Urinary Retention, Underactive Bladder
Interventions: Medtronic Interstim II Model 3058 Neurostimulator; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pancreatic Disease
Interventions: Combined EUS, e-PFT and sEUS Testing; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Generalized Anxiety Disorder
Interventions: Active LIFUP Treatment, Sham LIFUP Treatment; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Charleston, South Carolina

Conditions: Ischemic Stroke, Upper Extremity Problem
Interventions: Vivistim System; Device
Lead sponsor: MicroTransponder Inc.; Industry
Eligibility: 19 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infertility
Interventions: Embryo cryopreservation, Fresh blastocyst transfer; Procedure
Lead sponsor: Fertility Center of Las Vegas; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Brain Concussion, Mild Traumatic Brain Injury, Motor Disorders, Cognitive Impairment
Interventions: tDCS in Youth with mild traumatic brain injury; Device
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 10 Years to 15 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Brain Tumors, Central Nervous System Tumors, Neuroblastoma
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, vincristine sulfate, adjuvant therapy, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2012
U.S. locations: 35
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 27 more

Conditions: Healthy Subjects (HS)
Interventions: vagus nerve stimulation; Device
Lead sponsor: Youngstown State University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Youngstown, Ohio

Conditions: Depression
Interventions: Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Perinatal Depression, Post Partum Depression, Major Depressive Disorder
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Melanoma
Interventions: Ipilimumab, GM-CSF; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Dementia, Cognitive Impairment, Mild, Dementia, Vascular, Dementia, Mixed, Dementia With Lewy Bodies, Dementia Frontal, Dementia Moderate, Dementia of Alzheimer Type, Dementia, Mild
Interventions: Referral for Cognitive Stimulation Therapy, No change to Standard of Care; Behavioral · Other
Lead sponsor: University of Massachusetts, Amherst; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Farmington, Connecticut • New Haven, Connecticut

Conditions: Parkinson Disease Dementia
Interventions: Non-invasive brainstem stimulation; Device
Lead sponsor: Scion NeuroStim; Industry
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Boca Raton, Florida • Kansas City, Kansas

Conditions: Cognitive Change
Interventions: Anodal left dorsolateral prefrontal cortex tDCS stimulation, Anodal right dorsolateral prefrontal cortex tDCS stimulation, Sham tDCS stimulation; Device
Lead sponsor: Tufts University; Other
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Medford, Massachusetts

Conditions: Alzheimer Disease, Cognitive Change, Cognitive Impairment
Interventions: BUD1, BUD2, TDD1, TDD2, CSA10, CSA20, CSA30, CSA40; Behavioral
Lead sponsor: Clemson University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Seneca, South Carolina

Conditions: Autism Spectrum Disorder
Interventions: trans cranial direct current stimulation (tDCS), Sham; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 5 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Dalls, Texas

Conditions: Hematological Malignancies
Interventions: Cyclophosphamide, Thiotepa, Fludarabine, Melphalan, Mesna, G-CSF, Mycophenolate mofetil, Tacrolimus, Methylprednisolone, Total lymphoid irradiation, Lymphocyte infusions, CliniMACS; Drug · Biological · Radiation + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

FITLIGHT Reliability and Acute Training Effects

Sensory Synchronized Imaging and Neuromodulation

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

Modulation of Sensory Acuity With Transcranial Magnetic Stimulation (TMS)

Feasibility Study: tDCS for Treatment of Refractory Status Epilepticus

Repetitive Transcranial Magnetic Stimulation to Promote Regeneration in Persons With SCI

Previously Implanted Pudendal Nerve Stimulation

EUS Ductal Evaluation in One Endoscopic Session for the Diagnosis of Exocrine Pancreas Disease

Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)

VNS-REHAB At-Home - Post-Market Study for Using the Vivistim System® at Home

Comparison of Transfers of Fresh and Thawed Embryos in High Responder Patients

Neuromodulation and Neuroimaging in Older Children With Mild Traumatic Brain Injury

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

Vagus Nerve Stimulation for Reaction Time

EEG Synchronized TMS Trial for Depression

Accelerated TMS for Perinatal Depression

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial

SHARPEN - Parkinson's Disease Dementia

Decision Making in Video Games

Elucidating the Necessary Active Components of Training

Cerebellar Transcranial Direct Current Stimulation (tDCS) in Children With Autism Spectrum Disorder: Raynor Cerebellum Project

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen